TOP STORIES

• COMMENTARY Women’s Health Drugs on a Roll, Further Growth Expected as Public Awareness Rises
  December 19, 2023

• REGULATORY Chuikyo Split on Copay Rate under Elective Care Scheme; Political Decision Likely over 1/2 or 1/4
  December 18, 2023

• BUSINESS Cheplapharm Initiates LLP Acquisitions in Japan, Eyes 10 Asset Takeovers in 2024: Local Head
  December 15, 2023

• REGULATORY Japan OKs FY2024 Tax Reform Outline, “Innovation Box” Scheme Etched
  December 15, 2023

• REGULATORY Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing
  December 14, 2023

• REGULATORY Shionogi’s Novel Antibiotic Fetroja Gets Fast-Track Listing for Dec. 20
  December 14, 2023

• REGULATORY Leqembi OK’ed for Listing on Dec. 20; Peak Sales Put at 98.6 Billion Yen
  December 13, 2023

• BUSINESS Sobi Eyes Japan Approval of 4 Rare Disease Drugs in 5 Years: Local Chief
  December 12, 2023

• REGULATORY Japan Reform Minister Calls for Roadmap to Eliminate “Switch Lags” in 3 Years
  December 12, 2023

• REGULATORY Japan Panel OKs Basic Plan for Elective Care Scheme for LLPs; 900 APIs Targeted
  December 11, 2023

• REGULATORY Will R&D Tax Credit Be Scaled Back with “Innovation Box” Rollout? Political Settlement Likely
  December 8, 2023

• REGULATORY Sawai’s Revlimid Generic, BMS’ AG Now Available; Trerief AG Launch Set for Feb. 20
  December 8, 2023

• REGULATORY First Generics for 5 APIs to Join NHI Price List; No Entries for Januvia, Zytiga
  December 7, 2023

• REGULATORY CEFP Discusses Social Security Reform Timeline, No Surprises for Pharma Measures
  December 6, 2023

• BUSINESS Pfizer to Cut Ties with 3 Regional Wholesalers, Further Narrowing Expected
  December 5, 2023

• REGULATORY Authorized Generics Cannot be Regulated Now but Must Be Watched Closely: MHLW Panel Members
  December 5, 2023

• REGULATORY Proposed Introduction of Elective Care Scheme for LLP Copay “Hard to Understand”: Chuikyo Members
  December 4, 2023

• REGULATORY Average NHI-Market Price Gap for 2024 Revision at 6.0%, Smallest in 30 Years
  December 1, 2023

• REGULATORY No Consensus on PMP Company Criteria, Likely Review for Spillover Rule: Chuikyo
  November 30, 2023

• BUSINESS Bayer Set to Continue Stepping Up External Collaborations to Develop New Drugs: Regional BD Chief
  November 30, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• 56
• 57
• …
• Next ›
• 最終 »